Literature DB >> 12620606

The mu-opioid agonist remifentanil attenuates hyperalgesia evoked by blunt and punctuated stimuli with different potency: a pharmacological evaluation of the freeze lesion in humans.

Jörn Lötsch1, Martin S Angst.   

Abstract

Experimental pain models inducing hyperalgesia, i.e. an increased sensitivity to noxious stimuli often present in clinical pain, are important tools for studying antinociceptive drug profiles. The correct interpretation of results obtained in these models necessitates their mechanistic understanding. This study evaluated the freeze lesion, an experimental model of hyperalgesia, in humans. Twelve healthy subjects were tested with mechanical (brush, punctuated and blunt) and electrical (5, 250, and 2000 Hz sine wave current) stimuli before and after freezing the skin, and during a computer-controlled infusion of the mu-opioid agonist remifentanil targeting five different plasma concentrations between 0 and 6 ng/ml in a two-staged, single occasion, randomized, and double blind study design. Pharmacodynamic modeling techniques were used to describe the effect of freezing and drug administration on the mechanical and electrical pain thresholds. Freezing the skin resulted in hyperalgesia to blunt and punctuated stimuli and lowered the respective pain threshold by 29 and 73%. Hyperalgesia to brushing or electrical stimuli was not detected. Remifentanil attenuated hyperalgesia to blunt stimuli about twice as potently as hyperalgesia to punctuated stimuli, as indicated by a significantly steeper linear relationship between the remifentanil plasma concentration and the increase of the pain threshold to blunt stimuli. Remifentanil attenuated electrical pain with greater potency for low frequency stimulation. The potency difference of remifentanil suggests that different neuronal mechanisms mediate hyperalgesia to blunt and punctuated stimulation. Absence of brush-evoked and electrical hyperalgesia is compatible with the view that mechanical hyperalgesia to blunt and punctuated stimulation of the freeze lesion is predominantly caused by a peripheral mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620606     DOI: 10.1016/s0304-3959(02)00349-4

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  14 in total

Review 1.  Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.

Authors:  Werner Siegmund; Christiane Modess; Eberhard Scheuch; Karen Methling; Markus Keiser; Ali Nassif; Dieter Rosskopf; Patrick J Bednarski; Jürgen Borlak; Bernd Terhaag
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  Spotlight on remifentanil for general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Necessity and risks of arterial blood sampling in healthy volunteer studies.

Authors:  Bruno Georg Oertel; Johannes Vermehren; Michael Zimmermann; Thomas Tao Huynh; Alexandra Doehring; Nerea Ferreiros; Stephan Senzel; Thomas Schmitz-Rixen; Matthias Erbe; Gerd Geisslinger; Sebastian Harder; Martin S Angst; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2012-10-01       Impact factor: 6.447

5.  Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.

Authors:  Lisa Felden; Carmen Walter; Carlo Angioni; Yannick Schreiber; Nils von Hentig; Nerea Ferreiros; Gerd Geisslinger; Jörn Lötsch
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

Review 6.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

7.  Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia.

Authors:  Jörn Lötsch; Carsten Skarke; Jutta Darimont; Michael Zimmermann; Lutz Bräutigam; Gerd Geisslinger; Alfred Ultsch; Bruno G Oertel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-18       Impact factor: 3.000

Review 8.  Translating nociceptive processing into human pain models.

Authors:  Martin Schmelz
Journal:  Exp Brain Res       Date:  2009-04-29       Impact factor: 1.972

9.  Determining heat and mechanical pain threshold in inflamed skin of human subjects.

Authors:  Martin S Angst; Martha Tingle; Nicholas G Phillips; Brendan Carvalho
Journal:  J Vis Exp       Date:  2009-01-14       Impact factor: 1.355

Review 10.  Remifentanil : a review of its analgesic and sedative use in the intensive care unit.

Authors:  Anna J Battershill; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.